Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥65 years old)

Summary Objective This long-term event monitoring (LEM) study was designed to evaluate the long-term lipid-lowering efficacy and safety of fluvastatin (Lochol® , Novartis A.G.) along with the incidence of cardiac and other events, and safety of fluvastatin in Japanese patients with hypercholesterole...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology 2011-01, Vol.57 (1), p.77-88
Main Authors: Itakura, Hiroshige, MD, Nakaya, Noriaki, MD, Kusunoki, Tadashi, MD, Shimizu, Naokata, MD, Hirai, Shunsaku, MD, Mochizuki, Seibu, MD, Ishikawa, Toshitsugu, MD
Format: Article
Language:English
Subjects:
Age Factors
Aged
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Cardiovascular
Cardiovascular Diseases - etiology
Cerebrovascular Disorders - etiology
Cholesterol - blood
Cholesterol, LDL - blood
Drug Monitoring
Elderly
Fatty Acids, Monounsaturated - adverse effects
Fatty Acids, Monounsaturated - therapeutic use
Female
Fluvastatin
Humans
Hypercholesterolemia
Hypercholesterolemia - drug therapy
Indoles - adverse effects
Indoles - therapeutic use
Local event monitoring
Male
Middle Aged
Prospective Studies
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective This long-term event monitoring (LEM) study was designed to evaluate the long-term lipid-lowering efficacy and safety of fluvastatin (Lochol® , Novartis A.G.) along with the incidence of cardiac and other events, and safety of fluvastatin in Japanese patients with hypercholesterolemia. Methods Patients ( n = 21,139) who started fluvastatin between April 1, 2000 and March 31, 2002, across 2563 centers in Japan were prospectively registered and followed up for 3 years (secondary prevention cohort) or 5 years (primary prevention cohort). Results Of the patients registered, 19,084 were included in this analysis. Levels of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) decreased significantly in the primary (−27.1% and −18.8%) and secondary (−25.3% and −18.4%) prevention cohorts. Reductions in LDL-C (−22.1 vs. −18.2%, p < 0.0001) and TC (−16.1 vs. −13.1%, p < 0.0001) levels were significantly greater among patients aged ≥65 than
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2010.09.003